Cambrex Completes $38 Million API Plant Expansion
Manufacturing capacity of company’s High Point facility now doubles as a result.
Cambrex, a contract development and manufacturing organization (CDMO) that offers drug substance, drug product, and analytical services across the entire drug lifecycle,has completed of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, NC. This expansion doubles the facility's manufacturing capacity, with new state-of-the-art analytical and chemical development laboratories, two new clinical manufacturing suites, and a small-scale commercial manufacturing operation with three work centers and 2,000-liter reactors.
The High Point capabilities complement those of previously acquired Snapdragon Chemistry, which specializes in R&D for API batch, and continuous flow process development. The combination of Snapdragon Chemistry and the expansion in High Point allows clients to utilize one vendor for flow chemistry scale-up from R&D through commercialization.
"When we began this project in 2021, our vision extended far beyond capacity," comments Tom Loewald, CEO, Cambrex. "We designed a facility that can continue to deliver on client needs as the industry evolves, with state-of-the-art technology and laboratory equipment, an energy-efficient infrastructure, and clinical to commercial manufacturing scale."
